Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery
Stephen S. Lane, Satish S. Modi, Robert P. Lehmann, Edward J. Holland
Journal of Cataract & Refractive Surgery
January 2007 (Vol. 33, Issue 1, Pages 53-58) Abstract |
Full Text |
Full-Text PDF (185 KB)
In the January 2006 issue, in the article “Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery” (J Cataract Refract Surg 2007;33:53-58), cyclooxygenase 2 inhibitor is incorrectly identified in the first sentence of the third paragraph. The correct sentence should read as follows: “Nepafenac (amfenac amide) is an effective cyclooxygenase 1 (COX1) and cyclooxygenase 2 (COX2) inhibitor.”
FULL TEXT